Comparative mortality from cardiovascular disease in patients with chrome renal failure, Nephrology Dialysis Transplantation, vol.9, issue.8, pp.1136-1142, 1994. ,
DOI : 10.1093/ndt/9.8.1136
Clinical epidemiology of cardiovascular disease in chronic renal disease, American Journal of Kidney Diseases, vol.32, issue.5, pp.112-119, 1998. ,
DOI : 10.1053/ajkd.1998.v32.pm9820470
Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management, Nephrology Dialysis Transplantation, vol.15, issue.90005, pp.58-68, 2000. ,
DOI : 10.1093/ndt/15.suppl_5.58
Accelerated Atherosclerosis in Prolonged Maintenance Hemodialysis, New England Journal of Medicine, vol.290, issue.13, pp.697-701, 1974. ,
DOI : 10.1056/NEJM197403282901301
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, vol.344, pp.1383-1389, 1994. ,
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, New England Journal of Medicine, vol.333, issue.20, pp.1301-1307, 1995. ,
DOI : 10.1056/NEJM199511163332001
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels, New England Journal of Medicine, vol.335, issue.14, pp.1001-1009, 1996. ,
DOI : 10.1056/NEJM199610033351401
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels, JAMA, vol.279, issue.20, pp.1615-1622, 1998. ,
DOI : 10.1001/jama.279.20.1615
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, The Lancet, vol.360, issue.9346, pp.1623-1630, 2002. ,
DOI : 10.1016/S0140-6736(02)11600-X
Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial???Lipid Lowering Arm (ASCOT-LLA), Drugs, vol.64, issue.Supplement 2, pp.1149-1158, 2003. ,
DOI : 10.2165/00003495-200464002-00005
Beyond lipid-lowering: effects of statins on endothelial nitric oxide, European Journal of Clinical Pharmacology, vol.104, issue.11, pp.719-731, 2003. ,
DOI : 10.1172/JCI200114453
Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis, Atherosclerosis, vol.131, issue.2, pp.229-236, 1997. ,
DOI : 10.1016/S0021-9150(97)00054-3
Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients, J Am Soc Nephrol, vol.9, pp.1277-1284, 1998. ,
Study of Heart and Renal Protection (SHARP), Kidney International, vol.63, pp.207-210, 2003. ,
DOI : 10.1046/j.1523-1755.63.s84.4.x
Premature cardiovascular disease in chronic renal failure, The Lancet, vol.356, issue.9224, pp.147-152, 2000. ,
DOI : 10.1016/S0140-6736(00)02456-9
Association Between Cholesterol Level and Mortality in Dialysis Patients, JAMA, vol.291, issue.4, pp.451-459, 2004. ,
DOI : 10.1001/jama.291.4.451
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients, Kidney International, vol.61, issue.1, pp.297-304, 2002. ,
DOI : 10.1046/j.1523-1755.2002.00109.x
Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics, Kidney and Blood Pressure Research, vol.27, issue.4, pp.259-266, 2004. ,
DOI : 10.1159/000080241
Results of a randomized controlled trial with atorvastatin in dialyzed diabetic patients (4D trial), Presented at the annual meeting of the, 2004. ,
Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups, The American Journal of Cardiology, vol.91, issue.5, pp.3-10, 2003. ,
DOI : 10.1016/S0002-9149(03)00003-1
New dimension of statin action on apoB atherogenicity, Clinical Cardiology, vol.124, issue.S1, pp.7-10, 2003. ,
DOI : 10.1002/clc.4960261304
benefit-risk assessment of Rosuvastatin 10 to 40 milligrams, The American Journal of Cardiology, vol.92, issue.4, pp.23-29, 2003. ,
DOI : 10.1016/S0002-9149(03)00779-3
Regression models and life tablets (with discussion), J Royal Stat Soc, vol.74, pp.187-220, 1972. ,
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction, JAMA: The Journal of the American Medical Association, vol.260, issue.13, pp.1917-1921, 1988. ,
DOI : 10.1001/jama.1988.03410130125037
Low density lipoprotein particle size and coronary artery disease, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.12, issue.2, pp.187-195, 1992. ,
DOI : 10.1161/01.ATV.12.2.187
Small, Dense Low-Density Lipoprotein Particles as a Predictor of the Risk of Ischemic Heart Disease in Men: Prospective Results From the Quebec Cardiovascular Study, Circulation, vol.95, issue.1, pp.69-75, 1997. ,
DOI : 10.1161/01.CIR.95.1.69
VLDL, Apolipoproteins B, CIII, and E, and Risk of Recurrent Coronary Events in the Cholesterol and Recurrent Events (CARE) Trial, Circulation, vol.102, issue.16, pp.1886-1892, 2000. ,
DOI : 10.1161/01.CIR.102.16.1886
Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis, American Journal of Kidney Diseases, vol.27, issue.1, pp.84-91, 1996. ,
DOI : 10.1016/S0272-6386(96)90034-7
Abnormalities in lipoprotein metabolism in hemodialysis patients, Kidney International, vol.56, pp.248-250, 1999. ,
DOI : 10.1046/j.1523-1755.1999.07166.x
Atherogenic lipoprotein phenotype in end-stage renal failure: Origin and extent of small dense low-density lipoprotein formation, American Journal of Kidney Diseases, vol.35, issue.5, pp.852-862, 2000. ,
DOI : 10.1016/S0272-6386(00)70255-1
Dyslipidemia and renal disease: pathogenesis and clinical consequences, Current Opinion in Nephrology and Hypertension, vol.10, issue.2, pp.195-201, 2001. ,
DOI : 10.1097/00041552-200103000-00007
LIPOPROTEIN ABNORMALITIES IN HEMODIALYSIS AND CONTINUOUS AMBULATORY PERITONEAL DIALYSIS PATIENTS, Renal Failure, vol.16, issue.4, pp.623-630, 2002. ,
DOI : 10.1081/JDI-120013966
Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis, Kidney International, vol.39, issue.4, pp.754-760, 1991. ,
DOI : 10.1038/ki.1991.92
Reduction of intermediate density lipoprotein by pravastatin in hemo-and peritoneal dialysis patients, Clin Nephrol, vol.43, pp.268-277, 1995. ,
Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients, Kidney International, vol.56, pp.134-136, 1999. ,
DOI : 10.1046/j.1523-1755.1999.07133.x
Effect of simvastatin on the lipid profile of hemodialysis patients, Kidney International, vol.56, pp.56-219, 1999. ,
DOI : 10.1046/j.1523-1755.1999.07157.x
Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis, American Journal of Kidney Diseases, vol.39, issue.2, pp.283-290, 2002. ,
DOI : 10.1053/ajkd.2002.30547
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial, The Lancet, vol.361, issue.9374, pp.2024-2031, 2003. ,
DOI : 10.1016/S0140-6736(03)13638-0
Comparison of the efficacy and safety of rosuvastatin versus atorvasatatin, simvastatin, and pravastatin across doses ,
Rosuvastatin: A Highly Effective New HMG-CoA Reductase Inhibitor, Cardiovascular Drug Reviews, vol.39, issue.Suppl B, pp.303-328, 2002. ,
DOI : 10.1111/j.1527-3466.2002.tb00099.x
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome, Nephrology Dialysis Transplantation, vol.18, issue.7, pp.1272-1280, 2003. ,
DOI : 10.1093/ndt/gfg074
Oxidative stress and endothelial function in chronic renal failure, J Am Soc Nephrol, vol.12, pp.2747-2752, 2001. ,
Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities, Atherosclerosis, vol.173, issue.1, pp.1-12, 2004. ,
DOI : 10.1016/S0021-9150(03)00239-9
Impaired endothelium-dependent vasodilatation in renal failure in humans, Nephrology Dialysis Transplantation, vol.16, issue.2, pp.302-306, 2001. ,
DOI : 10.1093/ndt/16.2.302
A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid, British Journal of Pharmacology, vol.57, issue.3, pp.406-412, 2001. ,
DOI : 10.1038/sj.bjp.0704070
THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure, Seminars in Dialysis, vol.10, issue.suppl 1, pp.111-117, 2003. ,
DOI : 10.1046/j.1525-139X.2003.160271.x
Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension, The American Journal of Cardiology, vol.86, issue.5, pp.514-518, 2000. ,
DOI : 10.1016/S0002-9149(00)01004-3
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease, Journal of Cardiac Failure, vol.3, issue.4, pp.249-254, 1997. ,
DOI : 10.1016/S1071-9164(97)90022-1